| Interaction Color Code | Clinical Bottom Line | Clinical Effects | Drug 1 effect | Drug 2 dose | Drug 2 effect | Management | |
|---|---|---|---|---|---|---|---|
| Lenacapavir Eplerenone | Yellow: Adjust dosing | Minimal data to guide interaction: weigh risks and benefits of using this combination | Potential increased risk of eplerenone adverse effects |
If coadministering in the setting of post-MI heart failure, eplerenone dose not to exceed 25 mg daily. If coadministered for hypertension, initiate eplerenone at 25mg daily. Dose not to exceed 25 mg twice daily. |
|||
| Darunavir Eplerenone 928 | Red: Avoid combination | Do not coadminister: Potential for increased eplerenone levels | Potential for increased risk of eplerenone adverse effects |
Contraindicated. Use alternative agents. |
|||
| Elvitegravir Eplerenone 206 | Red: Avoid combination | Do not coadminister: Potential for increased levels of eplerenone | Potential for increased risk of eplerenone adverse effects |
Contraindicated. Use alternative agents. |
